What is the primary driver behind the shift from net income to net loss in the first quarter of 2004?

The primary driver for the net loss of $40.4 million in the first quarter of 2004, compared to a net income of $20.6 million in the prior year's quarter, was the absence of a significant gain from discontinued operations seen in Q1 2003 ($69.2 million gain on sale of assets) and a reduction in R&D expenses due to pipeline prioritization and restructuring efforts.

How has Vertex's debt structure changed, and what is the impact of the debt exchange?

Vertex exchanged approximately $153.1 million of its 5% Convertible Subordinated Notes due in 2007 for an equal principal amount of newly issued 5.75% Convertible Senior Subordinated Notes due in 2011. This transaction effectively defers the repayment date for a substantial portion of its outstanding debt, providing more flexibility in managing its capital structure.

What is the status of Vertex's cash position and liquidity?

Vertex maintained a strong liquidity position, with $53.0 million in cash and cash equivalents and $467.6 million in marketable securities as of March 31, 2004, totaling $520.6 million. Management expects its cash, cash equivalents, and marketable securities to exceed $350 million by the end of 2004, indicating sufficient funds to support ongoing operations and development.

What are the significant ongoing liabilities or contingencies mentioned in the report?

A significant ongoing liability is the accrual of $59.9 million for restructuring and other expenses, primarily related to the estimated ongoing lease obligations for the Kendall Square Facility. Management actively seeks subtenancies to minimize these obligations, and the exact timing and amount of future payments are subject to significant estimates and potential changes.

VRTX 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. reported a net loss of $40.4 million for the first quarter of 2004, a significant shift from the $20.6 million net income reported in the same period of 2003. This loss is primarily attributed to increased research and development (R&D) expenses, partially offset by a decrease in restructuring costs and a favorable change in discontinued operations. Total revenues saw a modest increase to $17.5 million from $16.0 million year-over-year, driven by higher royalty income from Agenerase and the newly launched Lexiva, alongside increased collaborative revenues. The company completed an exchange of $153.1 million of its 2007 convertible notes for new 2011 notes, deferring a significant portion of its debt maturity. Management expects R&D expenses to remain comparable to 2003 levels, with a focus on viral and inflammatory diseases. Despite the current net loss, Vertex ended the quarter with a strong cash position of $53.0 million in cash and cash equivalents and $467.6 million in marketable securities, providing substantial liquidity for future operations and development, with management projecting year-end cash to exceed $350 million.

Key Highlights

1Reported a net loss of $40.4 million ($0.52 per share) for Q1 2004, compared to a net income of $20.6 million ($0.27 per share) in Q1 2003.
2Total revenues increased by 9.5% to $17.5 million, driven by higher royalty income from Agenerase and Lexiva, and increased collaborative revenue.
3Research and development expenses decreased by 19% to $41.7 million, reflecting pipeline prioritization and a workforce reduction following a June 2003 restructuring.
4Completed an exchange of $153.1 million in 2007 convertible notes for an equal principal amount of new 5.75% convertible notes due 2011, deferring debt maturity.
5Ended the quarter with $53.0 million in cash and cash equivalents and $467.6 million in marketable securities, totaling $520.6 million in liquid assets.
6Accrued restructuring and other expenses stood at $59.9 million, primarily related to the Kendall Square Facility lease obligation.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions